Literature DB >> 15579060

Propofol: therapeutic indications and side-effects.

Paul E Marik1.   

Abstract

Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent which is widely used for the induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is an oil at room temperature and insoluble in aqueous solution. Present formulations consists of 1% or 2% (w/v) propofol, 10% soybean oil, 2.25% glycerol, and 1.2% egg phosphatide. Disodium edetate (EDTA) or metabisulfite is added to retard bacterial and fungal growth. Propofol is a global central nervous system depressant. It directly activates GABA(A) receptors. In addition, propofol inhibits the NMDA receptor and modulates calcium influx through slow calcium ion channels. Propofol has a rapid onset of action with a dose-related hypnotic effect. Recovery is rapid even after prolonged use. Propofol decreases cerebral oxygen consumption, reduces intracranial pressure and has potent anti-convulsant properties. It is a potent antioxidant, has anti-inflammatory properties and is a bronchodilator. As a consequence of these properties propofol is being increasingly used in the management of traumatic head injury, status epilepticus, delirium tremens, status asthmaticus and in critically ill septic patients. Propofol has a remarkable safety profile. Dose dependent hypotension is the commonest complication; particularly in volume depleted patients. Hypertriglyceridemia and pancreatitis are uncommon complications. Allergic complications, which may include bronchospasm, have been reported with the formulation containing metabisulfite. In addition, this formulation has been demonstrated to result in the generation of oxygen free radicals. High dose propofol infusions have been associated with the "propofol syndrome"; this is a potentially fatal complication characterized by severe metabolic acidosis and circulatory collapse. This is a rare complication first reported in pediatric patients and believed to be due to decreased transmembrane electrical potential and alteration of electron transport across the inner mitochondrial membrane.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579060     DOI: 10.2174/1381612043382846

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  100 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

2.  Current approaches to the recognition and treatment of alcohol withdrawal and delirium tremens: "old wine in new bottles" or "new wine in old bottles".

Authors:  Theodore A Stern; Anne F Gross; Thomas W Stern; Shamim H Nejad; Jose R Maldonado
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 3.  Therapy of intracranial hypertension in patients with fulminant hepatic failure.

Authors:  Murugan Raghavan; Paul E Marik
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

4.  Effects of the anesthetic agent propofol on neural populations.

Authors:  Axel Hutt; Andre Longtin
Journal:  Cogn Neurodyn       Date:  2009-09-19       Impact factor: 5.082

5.  Treatment of Convulsive Status Epilepticus.

Authors:  Eric H Grover; Yara Nazzal; Lawrence J Hirsch
Journal:  Curr Treat Options Neurol       Date:  2016-03       Impact factor: 3.598

6.  Propofol Attenuates Lipopolysaccharide-Induced Monocyte Chemoattractant Protein-1 Production Through Enhancing apoM and foxa2 Expression in HepG2 Cells.

Authors:  Xin Ma; Jia-Yi Zhao; Zhen-Long Zhao; Jing Ye; Shu-Fen Li; Hai-Hong Fang; Miao-Ning Gu; Yan-Wei Hu; Zai-Sheng Qin
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

7.  Arginase II polymorphisms modify the hypotensive responses to propofol by affecting nitric oxide bioavailability.

Authors:  Gustavo H Oliveira-Paula; Fernanda Borchers Coeli-Lacchini; Letícia Perticarrara Ferezin; Graziele C Ferreira; Lucas C Pinheiro; Waynice N Paula-Garcia; Luis V Garcia; Jose E Tanus-Santos; Riccardo Lacchini
Journal:  Eur J Clin Pharmacol       Date:  2021-01-07       Impact factor: 2.953

8.  Emergency Neurological Life Support: Resuscitation Following Cardiac Arrest.

Authors:  Jonathan Elmer; Kees H Polderman
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

Review 9.  Emergency Neurological Life Support: Resuscitation Following Cardiac Arrest.

Authors:  Jon C Rittenberger; Stuart Friess; Kees H Polderman
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.210

10.  Propofol Inhibits NLRP3 Inflammasome and Attenuates Blast-Induced Traumatic Brain Injury in Rats.

Authors:  Jie Ma; Wenjing Xiao; Junrui Wang; Juan Wu; Jiandong Ren; Jun Hou; Jianwen Gu; Kaihua Fan; Botao Yu
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.